Skip to main content

Table 2 Laboratory findings of cases

From: Chordoma: a case series and review of the literature

 

Case 1

Case 2

Case 3

WBC (μ/L)

Pretreatment*

8900

9500

7650

Posttreatment**

4300

 

4270

HGB (g/dl)

Pretreatment*

13.4

11.9

12.2

Posttreatment**

12.1

 

10.9

PLT (μ/L)

Pretreatment*

245,000

342,000

267,000

Posttreatment**

158,000

 

145,000

AST (U/L)

Pretreatment*

34

32

45

Posttreatment*

53

 

67

ALT (U/L)

Pretreatment*

18

42

54

Posttreatment**

39

 

83

Creatinine (mg/dl)

Pretreatment*

0.8

1.2

0.98

Posttreatment*

0.91

 

1

Bilirubin total (mg/dl)

Pretreatment*

0.8

1

0.98

Posttreatment**

0.89

 

1

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, HGB hemoglobin, PLT platelet, WBC white blood cell, * before the start of the tyrosine kinase inhibitor, ** after the discontinue of tyrosine kinase inhibitor therapy. Case 2 treatment continues